H.C. Wainwright raised the firm’s price target on Legend Biotech to $86 from $85 and keeps a Buy rating on the shares. The company’s partner, Janssen – a division of Johnson & Johnson – reported Q3 aggregate revenues for Carvykti of $152M, implying 30% quarter-over-quarter growth, the analyst tells investors in a research note. The firm says Carvykti sales ramp continued apace in Q3.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
